Citizens JMP lowered the firm’s price target on Enovis (ENOV) to $55 from $62 and keeps an Outperform rating on the shares. Consolidated Q1 results in sales and adjusted EBITDA nearly matched consensus, and updated guidance for 2025 reflects the positive impacts of foreign exchange on the top-line range and the negative impact of tariffs on EPS and adjusted EBITDA, the firm says. The stock’s valuation does not fully capture the benefits and potential upside of the complete integration of the Lima acquisition, Citizens argues.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENOV:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue